Clinical study on treatment of Helicobacter pylori infection related chronic gastritis by modified Chaihu shugan powder combined with Helicobacter pylori eradication program

doi:10.3877/cma.j.issn.1674-1358.2017.05.014

Abstract

Abstract:

Objective

To investigate the correlation between the combination of Modified Chaihu shugan powder and Helicobacter pylori (Hp) eradication in the treatment of Hp infection.

Methods

Total of 120 patients with Hp infection-related chronic gastritis were randomly selected from January 2014 to June 2015. They were divided into control group (60 cases) and traditional Chinese medicine adjuvant therapy group (60 cases), randomly. Two groups of patients were treated before routine routine gastric examination, excluding malignant tumors caused by gastritis, the two groups suffering from gastritis type (superficial gastritis, atrophic gastritis) were not significantly different. The patients in the control group were treated with Hp alone, while the patients in the treatment group were treated with Chinese herbal medicine supplemented with Chaihu shugan powder. Gastric gastroscope assisted the two groups of patients after 5 weeks of treatment, 12 weeks of chronic gastritis endoscopy points to assess the two treatment methods in the treatment of Hp infection-related chronic gastritis on the effect.

Results

The total score of Traditional Chinese Medicine symptoms in the treatment group and the control group were (21.48 ± 2.35), (21.34 ± 3.21) and (9.12 ± 2.01), (13.28 ± 2.03), with significant differences (all P < 0.05). The effective rates of Hp infection-related chronic gastritis were 71.7% and 95.0% in the control group and the treatment group, respectively, with significant difference (χ² = 0.876, P = 0.328). The gastroscope integral of patients the two groups after treatment were (13.28 ± 2.03) and (9.12 ± 2.01), with significant difference (t = 2.364, P = 0.029).

Conclusion

Modified Huaihu shugan powder combined with Hp eradication program is superior to HP eradication therapy alone.

Key words: Modified Chaihu shugan powder, Gastric mucosa chronic inflammation, Helicobacter Pylori

Pinghui Shi, Li Liu. Clinical study on treatment of Helicobacter pylori infection related chronic gastritis by modified Chaihu shugan powder combined with Helicobacter pylori eradication program[J]. Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition), 2017, 11(05): 496-499.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-1358.2017.05.014

https://zhsyhlcgrbzz.cma-cmc.com.cn/EN/Y2017/V11/I05/496

Figures/Tables 3

References 25

[1]	张万岱, 胡伏莲, 萧树东, 等. 中国自然人群幽门螺杆菌感染的流行病学调查[J]. 现代消化及介入治疗,2012,15(5):265-270.
[2]	沈以理, 要全保. 慢性胃炎肠化及不典型增生80例中医病机证型分析[J]. 中医研究,2009,22(4):14-15.
[3]	中华医学会消化病学分会幽门螺杆菌学组, 全国幽门螺杆菌研究协作组. 第四次全国幽门螺杆菌感染处理共识报告[J]. 胃肠病学,2012,17(10):618-625.
[4]	颜光美主编. 药理学[M]. 北京: 高等教育出版社,2013:263-265.
[5]	Malfertheiner P, Selgrad M, Bornschein J. Helicobacter pylori: clinical management[J]. Curr Opin Gastroenterol,2013,28(6):608-614.
[6]	庞淑珍, 赵文星, 任莹. 10天序贯疗法与14天标准三联疗法根除幽门螺杆菌疗效比较[J]. 实用医学杂志,2009,25(18):3058-3060.
[7]	Urgesi R, Pelecca G, Gianci R, et al. Helicobacter pylori infection on: is sequential therapy superior to standard triple therapy. A single centre. Italian study in treatment-naive[J]. Can J Gastroenterol, 2014,25(6):315-318.
[8]	Tong JL, Ran ZH, Shen J, et al. Sequential therapy vs. standard triple therapies Helicobacter pylori infection : a meta-analysis[J]. J Clin Pharm Ther,2014,34(1):41-53.
[9]	Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific consensus guidelines for Helicobacter pylori infections[J]. J Gastroenterol Hepatol,2015,24(3):1587-1600.
[10]	成虹, 胡伏莲, 李江, 等. 铋钾对幽门螺杆菌株体外抗菌活性研究[J]. 胃肠病学和肝病学杂志,2012,17(7):543-546.
[11]	Gisbert JP, Calvet X, Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pyloris[J]. Aliment Phannacol Ther,2015,34(6):64-67.
[12]	Berning M, Krasz S, Miehlke S. Should quinolones come first in Helicobacter pylior therapy[J]. Therap Adv Gastroenterol, 2015,4(2):103-114.
[13]	Endo S, Ohkusa T, Saito Y, et al. Detection of Helicobacter pylori infection in early stage gastric cancer[J]. Cancer,2014,75(9):2203-2208.
[14]	王凯娟, 王润田. 中国幽门螺杆菌感染流行病学Meta分析[J]. 中华流行病学志,2010,24(6):443-446.
[15]	黄大未, 杨晋翔, 魏玥, 等. 中国南北方地区慢性萎缩性胃炎中医证候对比研究[J]. 北京中医药大学学报,2013,12(11):783-785.
[16]	林春香, 顾雁, 李玉红, 等. 放大胃镜对幽门螺杆菌相关性胃炎的诊断价值[J]. 中国内镜杂志,2012,13(8):789-791.
[17]	祝金泉, 杨建民, 钟杰, 等. 幽门螺杆菌表型与胃粘膜炎性细胞侵润的关系[J]. 实验与检验医学,2013,27(1):19-22.
[18]	林永辉, 杨行堂, 张丽, 等. Hp临床分离株对5种抗生素的耐药性分析[J]. 同济大学校报(医学版),2009,30(5):86-89.
[19]	蒲永文, 李薇, 薛波涛, 等. 从肝论治胃病经验[J]. 中医杂志,2006,47(7):495-496.
[20]	陈润花, 刘敏, 陈亮, 等. 幽门螺杆菌相关性慢性胃炎中医证候分布特点文献研究[J]. 中华中医药杂志,2013,28(6):1879-1882.
[21]	师宁, 苏泽琦, 李培彩, 等. 酒精性肝纤维化中医证候分类研究[J]. 中华中医药杂志,2013,28(7):2119-2122.
[22]	陈润花, 陈亮, 师宁, 等. 酒精性肝纤维化中医证型与肝纤4项,影像学及病理分期相关性研究[J]. 中国中医基础医学杂志,2013,19(10):1202-1204.
[23]	郑昱, 谢建群, 李萍, 等. 慢性糜烂性胃炎中医辨证与幽门螺杆菌感染相关性分析[J]. 中华中医药学刊,2007,25(6):1210-1211.
[24]	石雪迎, 赵凤志, 由江峰, 等. 3种中药有效成份对幽门螺杆菌培养滤液转化的人胃黏膜上皮细胞的杀伤作用[J]. 北京中医药大学学报,2007,30(7):454-457.
[25]	谢春娥, 薛晓轩. 中医药治疗幽门螺杆菌相关性胃病的研究进展[J]. 北京中医药大学学报:中医临床版,2013,20(1):53-56.

组别	例数	男/女（例）	平均年龄（ ± s，岁）	胃炎类型[例（%）]		治疗前中医症状总积分（ ± s，分）
组别	例数	男/女（例）	平均年龄（ ± s，岁）	浅表性胃炎	萎缩性胃炎	治疗前中医症状总积分（ ± s，分）
对照组	60	28/32	43.78 ± 10.12	45（75.00）	15（25.00）	22.99 ± 3.78
治疗组	60	31/29	42.17 ± 11.34	43（71.7）	17（28.3）	22.78 ± 3.54
统计量		χ² = 0.612	t =-0.123	χ² = 0.381		t = 0.067
P值		0.526	0.912	0.526		0.867

组别	例数	男/女（例）	平均年龄（ ± s，岁）	胃炎类型[例（%）]		治疗前中医症状总积分（ ± s，分）
组别	例数	男/女（例）	平均年龄（ ± s，岁）	浅表性胃炎	萎缩性胃炎	治疗前中医症状总积分（ ± s，分）
对照组	60	28/32	43.78 ± 10.12	45（75.00）	15（25.00）	22.99 ± 3.78
治疗组	60	31/29	42.17 ± 11.34	43（71.7）	17（28.3）	22.78 ± 3.54
统计量		χ² = 0.612	t =-0.123	χ² = 0.381		t = 0.067
P值		0.526	0.912	0.526		0.867

组别		中医症状总积分	t值	P值
对照组			3.257	0.023
	治疗前	21.34 ± 3.21
	治疗后	13.28 ± 2.03
治疗组			3.629	0.014
	治疗前	21.48 ± 2.35
	治疗后	9.12 ± 2.01^a
t值		2.364
P值		0.029

组别		中医症状总积分	t值	P值
对照组			3.257	0.023
	治疗前	21.34 ± 3.21
	治疗后	13.28 ± 2.03
治疗组			3.629	0.014
	治疗前	21.48 ± 2.35
	治疗后	9.12 ± 2.01^a
t值		2.364
P值		0.029

组别	例数	治疗前胃镜积分	治疗后胃镜积分	t值	P值
对照组	60	2.48 ± 0.87	1.89 ± 0.67	4.213	0.028
治疗组	60	2.32 ± 0.89	1.73 ± 0.72	2.978	0.035
t值		0.432	0.968
P值		0.645	0.324

Please choose a citation manager

Content to export